DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Jeffrey Bluestone
Jeffrey Bluestone
Regulatory T Cells (Tregs): Frequently Asked Questions
Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver
2823.Full.Pdf
At FOCIS 2016
Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New- Onset Type 1 Diabetes Mellitus
Cancer-Immunotherapy-Article.Pdf
AST 2015 Achievement Award and Grant Press Release
Regulatory T Cells: Essential Regulators of the Immune System
National Cancer Advisory Board Blue Ribbon Panel Roster
Powerful Connections CHAIRMAN’S MESSAGE
TCR-Transgenic T Cells + Than B7.2 in the Activation of Naive CD8 B7.1 Is a Quantitatively Stronger Costimulus
UCSF Department of Medicine Department UCSF and Apatient
Scientific Program
Differential Effects of Anti-B7-1 and Anti-B7-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse by Deborah J
Curriculum Vitae
New Development of Immune Checkpoints Blockade in Cancer Immunotherapy
Scientific Background Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation
Parker Institute for Cancer Immunotherapy and Cancer Research Institute Launch Collaboration on Cancer Neoantigens Researchers A
Top View
Cancer Immunotherapies from Magic Bullets to Super T Cells
Plan Ahead For
Transforming Medicine Forward-Looking Statements
A Human Anti-IL-2 Antibody That Potentiates Regulatory T Cells by a Structure-Based Mechanism
President Joseph R. Biden the White House 1600 Pennsylvania Avenue NW Washington, DC 20500
JDRF Autoimmunity Center Abstracts
Presented by Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium History and Evolution of Immunotherapy
Todd Brusko Biographical Sketch
Report on the 2018 Cancer, Autoimmunity, and Immunology Conference Colleen S
Targeting Interference of CTLA-4 Co-Inhibition to Tumour-Specific T-Cells to Enhance Activity and Reduce Toxicity
For Their Discovery of Cancer Therapy by Inhibition of Negative Immune
Subsets Antibodies Differentially Regulate Individual Th Fcr-Nonbinding Anti-CD3 Monoclonal Partial TCR Signals Delivered By
CTLA-4 Transmission of Inhibitory
Z:\2020 OPERATIONS\2020 TYPESET\Provention Bio Inc\06-02
Conference Report
From Research to Cure